AC Immune SA (ACIU) Income Statement
ACIU 2025 at a glance
Fiscal year ended December 31, 2025 · Swiss francsACIU revenue and net income
Where ACIU's revenue goes
2025Each bar shows an amount and its share of revenue. ACIU kept −1,971.6% of revenue as net income.
ACIU profit margins
ACIU growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −86.9% | −3.2% | −25.4% | −21.3% |
| Gross profit | — | −3.2% | — | −16.6% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ACIU income statement in Swiss francs
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CHF 3.6M | CHF 27.3M | CHF 14.8M | CHF 3.9M | CHF 944,000 | CHF 15.4M | CHF 110.5M | CHF 7.2M | CHF 20.3M | CHF 23.2M |
| Cost of revenue | CHF 0 | CHF 62.6M | CHF 54.6M | CHF 60.3M | CHF 62.3M | CHF 59.5M | CHF 50.4M | CHF 44.3M | CHF 32.7M | CHF 25.8M |
| Gross profit | CHF 3.6M | −CHF 35.3M | −CHF 39.8M | CHF 3.9M | −CHF 62.3M | −CHF 44.1M | CHF 60.0M | −CHF 37.1M | −CHF 12.4M | −CHF 2.6M |
| Research & development | CHF 56.4M | CHF 62.6M | CHF 54.6M | CHF 60.3M | CHF 62.3M | CHF 59.5M | CHF 50.4M | CHF 44.3M | CHF 32.7M | CHF 25.8M |
| Sales, general & admin | CHF 11.7M | CHF 11.4M | CHF 10.6M | CHF 9.6M | CHF 10.9M | CHF 18.6M | CHF 16.1M | CHF 7.6M | CHF 6.3M | CHF 4.7M |
| Total operating expenses | CHF 72.4M | CHF 17.1M | CHF 13.8M | CHF 74.8M | CHF 79.0M | CHF 17.2M | CHF 15.5M | CHF 56.7M | CHF 42.8M | CHF 33.7M |
| Operating income | −CHF 68.9M | −CHF 52.4M | −CHF 53.6M | −CHF 70.8M | −CHF 79.0M | −CHF 61.3M | CHF 44.5M | −CHF 49.5M | −CHF 22.5M | −CHF 10.5M |
| Interest income | CHF 1.9M | CHF 3.2M | CHF 1.0M | CHF 69,000 | CHF 6.5M | CHF 78,000 | CHF 304,000 | CHF 29,000 | CHF 330,000 | CHF 43,000 |
| Interest expense | CHF 191,000 | CHF 133,000 | CHF 176,000 | CHF 355,000 | CHF 581,000 | CHF 184,000 | CHF 1.9M | CHF 334,000 | CHF 147,000 | CHF 256,000 |
| Income before taxes | −CHF 70.4M | −CHF 50.9M | −CHF 54.2M | −CHF 70.7M | −CHF 73.0M | −CHF 61.9M | CHF 45.4M | −CHF 51.0M | −CHF 26.4M | −CHF 7.1M |
| Income taxes | — | CHF 3,000 | CHF 10,000 | CHF 13,000 | CHF 3,000 | CHF 184,000 | CHF 1.9M | −CHF 1.1M | CHF 147,000 | CHF 3.6M |
| Net income | −CHF 70.4M | −CHF 50.9M | −CHF 54.2M | −CHF 70.8M | −CHF 73.0M | −CHF 61.9M | CHF 45.4M | −CHF 51.0M | −CHF 26.4M | −CHF 7.1M |
| EBITDA | −CHF 67.8M | −CHF 48.6M | −CHF 51.8M | −CHF 68.0M | −CHF 70.0M | −CHF 59.3M | CHF 46.2M | −CHF 49.7M | −CHF 22.5M | −CHF 6.8M |
| Gross margin | 100.0% | −129.1% | −268.9% | 100.0% | −6,597.7% | −285.5% | 54.3% | −515.5% | −61.3% | −11.0% |
| Operating margin | −1,927.3% | −191.8% | −362.3% | −1,800.4% | −8,369.7% | −397.0% | 40.3% | −688.8% | −111.3% | −45.0% |
| Net margin | −1,971.6% | −186.4% | −366.4% | −1,798.0% | −7,732.6% | −401.3% | 41.1% | −708.2% | −130.4% | −30.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CHF 15.1M | CHF 1.1M | CHF 338,000 | CHF 939,000 | CHF 1.3M | CHF 990,000 | CHF 1.1M | CHF 25.5M | CHF 687,000 | CHF 687,000 | CHF 14.8M | CHF 0 |
| Cost of revenue | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 14.5M | CHF 17.1M | CHF 15.2M | CHF 14.6M | CHF 12.4M |
| Gross profit | CHF 15.1M | CHF 1.1M | CHF 338,000 | CHF 939,000 | CHF 1.3M | CHF 990,000 | CHF 1.1M | CHF 25.5M | CHF 687,000 | −CHF 15.2M | CHF 14.8M | −CHF 12.4M |
| Research & development | CHF 10.5M | CHF 11.7M | CHF 10.5M | CHF 13.1M | CHF 16.8M | CHF 15.9M | CHF 15.8M | CHF 14.5M | CHF 17.1M | CHF 15.2M | CHF 14.6M | CHF 12.4M |
| Sales, general & admin | CHF 3.5M | CHF 4.2M | CHF 254,000 | CHF 3.6M | CHF 3.9M | CHF 4.4M | CHF 1.8M | CHF 3.8M | CHF 4.6M | CHF 5.0M | CHF 676,000 | CHF 3.5M |
| Total operating expenses | CHF 13.9M | CHF 15.9M | CHF 14.7M | CHF 17.1M | CHF 20.7M | CHF 20.4M | CHF 19.8M | CHF 18.2M | CHF 21.6M | CHF 20.1M | CHF 18.3M | CHF 15.5M |
| Operating income | CHF 1.2M | −CHF 14.8M | −CHF 14.4M | −CHF 16.2M | −CHF 19.4M | −CHF 19.4M | −CHF 18.6M | CHF 7.3M | −CHF 21.0M | −CHF 20.1M | −CHF 3.5M | −CHF 15.5M |
| Interest income | CHF 171,000 | CHF 228,000 | CHF 353,000 | CHF 366,000 | CHF 458,000 | CHF 687,000 | CHF 889,000 | CHF 939,000 | CHF 739,000 | CHF 629,000 | CHF 291,000 | CHF 285,000 |
| Interest expense | CHF 61,000 | CHF 65,000 | CHF 41,680 | CHF 46,000 | CHF 50,000 | CHF 54,000 | CHF 30,000 | CHF 33,000 | CHF 34,000 | CHF 36,000 | CHF 26,000 | CHF 26,000 |
| Income before taxes | CHF 1.9M | −CHF 14.8M | −CHF 14.4M | −CHF 15.9M | −CHF 21.2M | −CHF 19.0M | −CHF 15.8M | CHF 5.5M | −CHF 22.8M | −CHF 17.9M | −CHF 4.7M | −CHF 15.1M |
| Income taxes | — | — | — | — | — | — | CHF 3,000 | — | — | CHF 36,000 | CHF 1,000 | CHF 3,000 |
| Net income | CHF 1.9M | −CHF 14.8M | −CHF 14.4M | −CHF 15.9M | −CHF 21.2M | −CHF 19.0M | −CHF 15.8M | CHF 5.5M | −CHF 22.8M | −CHF 17.9M | −CHF 4.7M | −CHF 15.1M |
| EBITDA | CHF 1.9M | −CHF 14.7M | −CHF 13.7M | −CHF 15.2M | −CHF 20.5M | −CHF 18.4M | −CHF 15.2M | CHF 6.1M | −CHF 22.2M | −CHF 17.3M | −CHF 4.2M | −CHF 14.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −2,207.4% | 100.0% | — |
| Operating margin | 7.9% | −1,321.5% | −4,262.1% | −1,721.6% | −1,484.5% | −1,956.6% | −1,637.5% | 28.5% | −3,051.1% | −2,921.1% | −23.9% | — |
| Net margin | 12.4% | −1,322.7% | −4,252.4% | −1,688.8% | −1,622.4% | −1,922.1% | −1,389.4% | 21.6% | −3,313.0% | −2,600.0% | −32.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in Swiss francs as reported in ACIU's financial statements (latest annual report filed March 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ACIU financial results
In fiscal year 2025 (ended December 31, 2025), AC Immune reported revenue of CHF 3.6 million, down 86.9% from the year before. It had a net loss of CHF 70.4 million, a net profit margin of −1,971.6%. Over five years revenue grew at an average rate of −25.4% a year. Figures are in Swiss francs, the currency of its financial statements.
See the ACIU stock overview for the latest quote and news, or the ACIU chart for price history and technical indicators.
ACIU income statement FAQ
What is AC Immune's annual revenue?
AC Immune reported total revenue of CHF 3.6 million for fiscal year 2025, which ended on December 31, 2025. That was down 86.9% from CHF 27.3 million the previous year.
Is AC Immune profitable?
No. AC Immune reported a net loss of CHF 70.4 million in fiscal 2025, a net profit margin of −1,971.6%; its operating margin was −1,927.3%.
What is AC Immune's gross margin?
AC Immune's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, AC Immune kept $100 after the direct cost of its products and services.
How much does AC Immune spend on research and development?
AC Immune spent CHF 56.4 million on research and development in fiscal 2025, 1,579.5% of revenue.
How fast is AC Immune growing?
Revenue grew −25.4% a year on average over the last five fiscal years, from CHF 15.4 million to CHF 3.6 million.
When will AC Immune report its next earnings?
AC Immune is expected to report results for the quarter ending September 30, 2026 on November 3, 2026.
When does AC Immune's fiscal year end?
AC Immune's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 13, 2026.